Characterization of GRPR expression patterns in specific histological subtypes of uterine cervix cancer may help in defining patient population(s) who benefit from 212Pb-DOTAM-GRPR1 as a radiopharmaceutical treatment. The gene discussed is GRPR; the disease is cervical cancer.